n | Pathologic response | Univariate analysis | Multivariate analysis | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CR n = 16 (%) | Non-CR n = 39 (%) | OR | 95% CI | p | OR | 95 % CI | p | ||||
Lower | Upper | Lower | Upper | ||||||||
Body mass index (BMI) | ≤ 29.6 (n = 31) | 9 (29) | 22 (71) | 1.1 | 0.3 | 3.6 | 0.8 | ||||
> 29 (n = 24) | 7 (29) | 17 (71) | |||||||||
Metabolic syndrome | Yes (n = 22) | 5 (23) | 17 (77) | 1.9 | 0.5 | 6.6 | 0.2 | ||||
No (n = 33) | 11 (33) | 22 (63) | |||||||||
Insulin resistance | No (n = 25) | 11 (44) | 14 (56) | 4.6 | 1.3 | 15.9 | 0.02 | 4.7 | 1.7 | 17.2 | 0.01 |
Yes (n = 30) | 5 (16) | 25 (84) | |||||||||
NLR | ≤ 3.3 (n = 26) | 9 (35) | 17 (65) | 1.9 | 0.6 | 6.2 | 0.8 | ||||
> 3.3 (n = 29) | 7 (24) | 22 (76) | |||||||||
SII | ≤ 963 (n = 28) | 10 (36) | 18 (74) | 2.2 | 0.6 | 7.1 | 0,1 | ||||
> 963 (n = 27) | 6 (22) | 21 (78) | |||||||||
PLR | ≤ 225.3 (n = 27) | 11 (40) | 16 (60) | 2.5 | 0.7 | 8.2 | 0.06 | ||||
> 225.3 (n = 28) | 5 (18) | 23 (82) | |||||||||
CRP | < 5 (mg/L) (n = 38) | 10 (26) | 28 (74) | 1.3 | 0.3 | 4.5 | 0.6 | ||||
≥ 5 (mg/L) (n = 17) | 6 (35) | 11 (65) | |||||||||
Ki 67 index | ≤ 15 (n = 13) | 2 (18) | 11 (82) | 0.3 | 0.6 | 1.67 | 0.1 | ||||
> 15 (n = 42) | 14 (33) | 28 (67) | |||||||||
Her-2 status | Positive (n = 16) | 7 (44) | 9 (56) | 0.5 | 0.1 | 1.97 | 0.3 | ||||
Negative (n = 39) | 9 (23) | 30 (77) | |||||||||
Estrogen receptor status | Positive (n = 40) | 10 (25) | 30 (75) | 1.7 | 0.5 | 6.1 | 0.3 | ||||
Negative (n = 15) | 6 (40) | 9 (60) | |||||||||
Progesterone receptor status | Positive (n = 31) | 5 (16) | 26 (84) | 3.5 | 1.0 | 11.6 | 0.01 | 3.6 | 1.0 | 13.0 | 0.04 |
Negative (n = 9) | 5 (55) | 4 (45) |